- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Spago Nanomedical Interim Report January-March 2024 | 194 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important yearJANUARY - MARCH IN BRIEFNet sales for the quarter amounted to KSEK 350 (KSEK... ► Artikel lesen | |
| 24.04. | Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad | 178 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from a non-clinical study exploring 177Lu-SN201 in a model for... ► Artikel lesen | |
| 23.04. | Spago Budapest Offering Unique Sunday Brunch Experience | - | BBJ online | ||
| 16.04. | Spago Nanomedical Strengthens Management with Head of CMC & Supply | 219 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / April 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced the appointment of Birgitta Rembratt Svensson as Head of CMC & Supply.... ► Artikel lesen | |
| 27.03. | Spago Nanomedical's CEO: "huge commercial opportunities are unfolding" | 1 | Cision News | ||
| 09.02. | 2023 springboard for Spago's radionuclide cancer therapy | - | Cision News | ||
| 07.02. | Spago Nanomedical Year-end Report January-December, 2023 | 286 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) First cancer patient dosed with Tumorad®OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK... ► Artikel lesen | |
| 02.02. | Spago Budapest Introduces New High-end Lunch Menu | - | BBJ online | ||
| 18.01. | Spago Nanomedical Presents at Redeye's Fight Cancer Event on January 24 | 231 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / January 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company will participate at Redeye's Fight Cancer event... ► Artikel lesen | |
| 15.01. | Spago's phase I/IIa cancer trial progressing steadily | 1 | Cision News | ||
| 10.01. | Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01 | 357 | ACCESSWIRE | LUND, SE / ACCESSWIRE / January 10, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent data monitoring committee has recommended a dose... ► Artikel lesen | |
| 20.12.23 | Nasdaq Stockholm AB: New equity right for trading, Spago Nanomedical AB (682/23) | 246 | GlobeNewswire | At the request of Spago Nanomedical AB, Spago Nanomedical AB equity right will
be traded on First North as from December 21, 2023.
Security name: Spago Nanomedical AB TO 12
------------------------------------------
Short... ► Artikel lesen | |
| 15.12.23 | Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 In Patients with Endometriosis | 288 | ACCESSWIRE | LUND, SE / ACCESSWIRE / December 15, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announces today that the analysis of data from the phase IIa clinical study SPAGOPIX-02... ► Artikel lesen | |
| 14.12.23 | First patient dosed in Spago's phase I/IIa trial | 3 | Cision News | ||
| 13.12.23 | Nasdaq Stockholm AB: Last day of trading in paid subscription units (BTU) of Spago Nanomedical AB (661/23) | 346 | GlobeNewswire | Trading in Spago Nanomedical AB paid subscription units is to cease. The last
trading day is December 15, 2023.
Short name: SPAGO BTU
---------------------------
ISIN code: SE0020998722
---------------------------
Orderbook... ► Artikel lesen | |
| 07.12.23 | First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIa Study within the Tumorad Program | 323 | ACCESSWIRE | LUND, SE / ACCESSWIRE / December 07, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the first cancer patient has successfully been dosed in the clinical... ► Artikel lesen | |
| 23.11.23 | Last Day of the Subscription Period in Spago Nanomedical's Rights Issue | 359 | ACCESSWIRE | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG-KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY... ► Artikel lesen | |
| 14.11.23 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2024 | 281 | ACCESSWIRE | LUND, SE / ACCESSWIRE / November 14, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| 09.11.23 | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 229 | ACCESSWIRE | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG-KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY... ► Artikel lesen | |
| 08.11.23 | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Spago Nanomedical AB (564/23) | 342 | GlobeNewswire | With effect from November 09, 2023, the unit rights in Spago Nanomedical AB
will be traded on First North Growth Market. Trading will continue up until and
including November 20, 2023.
Instrument:... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Evotec, HelloFresh, K+S, Lanxess, Rheinmetall, SMA Solar und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
SPAGO NANOMEDICAL AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,026 Euro und damit -8,51 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
